[CH3:1][C:2]1[C:7]([CH3:8])=[CH:6][CH:5]=[CH:4][C:3]=1[N:9]1[CH2:14][CH2:13][N:12]([CH2:15][CH:16]([OH:30])[CH2:17][CH2:18][N:19]2C(=O)C3C(=CC=CC=3)C2=O)[CH2:11][CH2:10]1.O.NN>C(O)C>[NH2:19][CH2:18][CH2:17][CH:16]([OH:30])[CH2:15][N:12]1[CH2:11][CH2:10][N:9]([C:3]2[CH:4]=[CH:5][CH:6]=[C:7]([CH3:8])[C:2]=2[CH3:1])[CH2:14][CH2:13]1To a mixture of 2-(4-(4-(2,3-dimethylphenyl)piperazin-1-yl)-3-hydroxybutyl)isoindoline-1,3-dione obtained in step 4 (0.26 g, 0.65 mmol) in ethanol (1.5 ml), was added hydrazine monohydrate (0.063 ml, 2.02 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 17 hours. After the reaction complete, the reaction mixture thus obtained was sonicated and filtered. The filtrate was concentrated under reduced pressure. The residue was extracted with ethyl acetate and water. The organic phase thus separated was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (0.1 g). The compound was used for the next step without further purification.